tbuckley/cabot-search huggingface dataset:
Time Trends in Systemic Adjuvant Treatment for Node-Negative Breast Cancer
Authors: Nicole Hébert-Croteau, Jacques Brisson, Jean Latreille, Gilles Gariépy, Caty Blanchette, Luc Deschênes
Journal: Journal of Clinical Oncology (1999)

PURPOSE: We conducted a population-based study in Quebec, Canada, to assess longitudinal changes in systemic adjuvant therapy for node-negative breast cancer. MATERIALS AND METHODS: A stratified random sample was selected among women with newly diagnosed node-negative breast cancer in 1988, 1991, and 1993. Information on the patient, her tumor, source of care, and treatment was abstracted from medical charts. Patients were classified as being at minimal, moderate, or high risk of recurrence on the basis of criteria proposed at the 4th International Conference on Adjuvant Therapy of Primary Breast Cancer (St. Gallen, Switzerland, 1992), and systemic adjuvant treatment received was dichotomized as being consistent or not consistent with consensus recommendations. RESULTS: Overall, 1,578 cases of invasive breast carcinoma were reviewed. The proportion of patients who were given hormonal or cytotoxic treatment increased from 51.7% to 73.1% from 1988 to 1993. Virtually all women at minimal risk were treated in 1991 and 1993 according to the consensus statement. The proportions of women so treated were 75.0% and 65.4% in the moderate- and high-risk categories, respectively, in 1991. In 1993, these proportions were 71.4% and 67.0%, respectively. Omission of chemotherapy, especially in high-risk women with estrogen receptor–negative tumors who were 50 to 69 years of age, was the most frequent inconsistency with guidelines. CONCLUSION: Systemic adjuvant therapy for node-negative breast cancer has gained acceptance. Better understanding of the decision-making process, of the perception of the risks and benefits involved, and of the impact of alternative strategies for the dissemination of consensus recommendations are needed to promote the use of chemotherapy in specific categories of women who are at high risk of recurrence.
Is the ESGE guideline recommendation against the placement of stents for left-sided malignant colonic obstruction still open to debate?
Authors: Min Kim
Journal: Endoscopy (2016)

We have developed an interest recently in the subject of self-expandable metallic stent (SEMS) placement for obstructive, left-sided, colonic cancer. On reviewing the published literature on this topic, we noted that the European Society of Gastrointestinal Endoscopy (ESGE) guideline published in 2014 recommends not to use SEMS as a standard treatment for symptomatic, left-sided, malignant, colonic obstruction [1].
Spending on hospital equipment is underfunded by ?8m in Scotland.
Authors: Bryan Christie
Journal: BMJ (2001)

Hospitals in Scotland are failing to invest adequately in medical equipment, which could result in putting patients at risk, says a report from the auditor general for Scotland. It has recommended the establishment of a rolling programme of planned replacement.

Underfunding of around £8m ($12m) was identified in 1997-8. Although the report acknowledges that figures for one year need to be treated with caution, it added: “Our survey findings suggest that across Scotland, expenditure on new and replacement medical equipment is failing to match depreciation and that trusts are not replacing items of medical equipment when they come to the end of their useful lives.”

The report also found that more than 40% of health trusts had no formal training policies for using medical equipment. That was a matter of concern because the Medical Devices Agency had produced figures showing that patients were 3-10 times more likely to be at risk from error by users than from faulty equipment.
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
Authors: A. Kaifie, M. Kirschner, D. Wolf, C. Maintz, M. Hänel, N. Gattermann, E. Gökkurt, U. Platzbecker, W. Hollburg, J. R. Göthert, S. Parmentier, F. Lang, R. Hansen, S. Isfort, K. Schmitt, E. Jost, H. Serve, G. Ehninger, W. E. Berdel, T. H. Brümmendorf, S. Koschmieder
Journal: Journal of Hematology & Oncology (2016)

Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at increased risk for thrombosis/thromboembolism and major bleeding. Due to the morbidity and mortality of these events, antiplatelet and/or anticoagulant agents are commonly employed as primary and/or secondary prophylaxis. On the other hand, disease-related bleeding complications (i.e., from esophageal varices) are common in patients with MPN. This analysis was performed to define the frequency of such events, identify risk factors, and assess antiplatelet/anticoagulant therapy in a cohort of patients with MPN. The MPN registry of the Study Alliance Leukemia is a non-interventional prospective study including adult patients with an MPN according to WHO criteria (2008). For statistical analysis, descriptive methods and tests for significant differences as well as contingency tables were used to identify the odds of potential risk factors for vascular events. MPN subgroups significantly differed in sex distribution, age at diagnosis, blood counts, LDH levels, JAK2V617F positivity, and spleen size (length). While most thromboembolic events occurred around the time of MPN diagnosis, one third of these events occurred after that date. Splanchnic vein thrombosis was most frequent in post-PV-MF and MPN-U patients. The chance of developing a thromboembolic event was significantly elevated if patients suffered from post-PV-MF (OR 3.43; 95 % CI = 1.39–8.48) and splenomegaly (OR 1.76; 95 % CI = 1.15–2.71). Significant odds for major bleeding were previous thromboembolic events (OR = 2.71; 95 % CI = 1.36–5.40), splenomegaly (OR = 2.22; 95 % CI 1.01–4.89), and the administration of heparin (OR = 5.64; 95 % CI = 1.84–17.34). Major bleeding episodes were significantly less frequent in ET patients compared to other MPN subgroups. Together, this report on an unselected "real-world" cohort of German MPN patients reveals important data on the prevalence, diagnosis, and treatment of thromboembolic and major bleeding complications of MPN.
Leukocyte Migration inhibition Response to Various Antigen Preparations of Autologous and Homologous Breast Cancer in Patients With Primary Breast Cancer<xref ref-type="fn" rid="FN2">2</xref>
Authors: M Fukuda, H J Wanebo, L Tsuei, N H Sarkar
Journal: JNCI Journal of the National Cancer Institute (1979)

The direct leukocyte migration inhibition test was used to measure the host response to antigen preparations of autologous and homologous breast cancer and normal breast tissue, a panel of cancerous and normal colon tissue, and three breast cancer cell lines: MCF-7, CAMA, and MD-MBA-231. A total of 96 patients with primary operable breast cancer, 22 patients with benign breast disease, 10 patients with head and neck cancer, and 40 normal women were tested. The migration index (MI) equivalent to the tenth percentile of the control response to individual antigens was used as the cutoff point determining the level of positive response. Only 19% of 62 patients responded to cryostat sections of autologous cancer versus a 9% response to autologous normal breast tissue (P= not significant). Similar responses were observed with the use of saline extracts of these tissues. Positive response (MI < 0.93) to a panel of cryostat sections of homologous breast cancer antigens occurred in 44% of 96 patients with breast cancer, 15% of 39 patients with benign breast disease, and 12% of 140 normal women (P<0.01). A similar pattern of response was observed with the use of saline extracts of these tissues, but none of the patients responded to saline extracts of normal or malignant colon tissue. The response to the MCF-7 breast cancer cell line was also significantly higher in the patients with breast cancer (50%) than in normal persons (9%) or in patients with head and neck cancer (10%, P<0.01) but was not significantly higher than responses in patients with benign breast disease (24%, P<0.1). The breast cancer patients showed variable response to two other breast cancer cell lines, CAMA (23% positive) and MD-MBA-231 (15% positive), which may indicate quantitative or qualitative differences in antigenicity between these breast cancer cell lines. The leukocyte migration inhibition response rates to homologous breast cancer antigens suggest possible previous sensitization to these antigens in a portion of the breast cancer patients. Whether the antigenic determinants are common to many breast cancers or are also distinctive for individual cancers remains to be determined.
Abstract 12504: Relation between Blood Pressure Lowering Therapy and Cardiovascular Events in Hypertensive Patients With Coronary Artery Disease and Chronic Kidney Disease -The HIJ-CREATE Sub-study
Authors: Hiroshi Ogawa, Erisa Kawada-Watanabe, Dai Okayama, Hiroyuki Arashi, Jun-ichi Yamaguchi, Atsushi Takagi, Nobuhisa Hagiwara
Journal: Circulation (2013)

Purpose: To explore the optimal blood pressure target in hypertensive patients with coronary artery disease (CAD) and chronic kidney disease (CKD) in the substudy of the HIJ-CREATE trial. Methods: HIJ-CREATE was a prospective, randomized trial that compared the effects of candesartan-based therapy with those of non-ARB standard therapy on MACE in 2049 hypertensive patients with CAD. Among them, CKD defined as a decrease in creatinine clearance calculated using the abbreviated MDRD formula to ≤ 60 ml/min. was recognized in 1002 patients. In the present study, titration of antihypertensive agents was performed to reach the target blood pressure (BP) of ≤130/85 mmHg. The primary endpoint was the time to first major adverse cardiac events (MACE). Incidence of MACEs in addition to biochemistry tests and office BP was determined during the scheduled 6, 12, 24, 36, 48, and 60 month visits. Achieved BP were defined as the mean value of systolic BP in patients who did not meet with MACE and the mean value of systo...
Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice
Authors: Nikolaos Manitsopoulos, Nikolaos Maniatis, Ioanna Nikitopoulou, Christina Magkou, Apostolos Armaganidis, Anastasia Kotanidou, Stylianos Orfanos
Journal: European Respiratory Journal (2013)

Pulmonary fibrosis is a progressive disorder leading to respiratory failure. Endothelin-1 (ET-1) is a potent vasoconstrictor, and inducer of fibrocyte and smooth muscle proliferation but its role in pulmonary fibrosis is still under investigation. We aimed to investigate the effect of selective ET-1 A (ETA) receptor blockade in the pathogenesis of pulmonary fibrosis.

Adult male C57BL6 mice (4 groups; n=6-10/group) were injected intratracheally with bleomycin sulfate (BLM; 2mg/mL) or saline. Treatment with the specific ETA receptor inhibitor sitaxentan at 15mg/kg/day through drinking water, or with H2O, started one day prior to BLM injection. Mice were sacrificed at day 7, 14 and 21 post BLM, after evaluation of lung mechanics. Bronchoalveolar lavage fluid (BALF) and lung tissue samples were obtained.

BLM exposure caused: i) a deterioration of lung elastance and compliance, ii) lung histological injury, and iii) increased cellularity and protein content in BALF, at all time points. Sitaxentan administration had no effect in naive mice, while in BLM-treated mice it improved lung mechanics, attenuated lung pathology and BALF pleiocytosis at all time points, and decreased BALF protein content at day 21. BLM increased tissue collagen deposition at day 21 from 200.5±18.7 (controls) to 294.4±29.8 µg/mL, denoting fibrosis, while sitaxentan administration decreased it to 219.4±5.6 (Mean±SEM; p<0.05 by ANOVA).

In conclusion, prophylactic specific ETA receptor blockade preserves lung function, reduces airspace inflammation and lung pathology, and prevents collagen deposition in our model. ETA receptor inhibition may be a promising approach to the treatment of pulmonary fibrosis.
Neoadjuvant treatment with Bevacizumab and FOLFOX-6 in patients with liver metastasis from colorectal cancer: preliminary results of a Phase II study.
Authors: F Bertolini, N Malavasi, C Dealis, S Zironi, R Depenni, A Fontana, R Sternieri, Giovanni Ponti, G Luppi, Pierfranco Conte
Journal: Annals of Oncology (2012)
Endoscopist characteristics that influence the quality of colonoscopy
Authors: Rodrigo Jover, Pedro Zapater, Luis Bujanda, Vicent Hernández, Joaquín Cubiella, Maria Pellisé, Marta Ponce, Akiko Ono, Angel Lanas, Agustín Seoane, José Marín-Gabriel, María Chaparro, Guillermo Cacho, Alberto Herreros-de-Tejada, Servando Fernández-Díez, Antonio Peris, David Nicolás-Pérez, Oscar Murcia, Antoni Castells, Enrique Quintero
Journal: Endoscopy (2016)

<b>Background and study aim:</b> Several factors have been shown to be related to colonoscopy quality; however, little is known about the effects of endoscopist factors. This study analyzed the influence of endoscopist-related characteristics on quality indicators for colonoscopy. <b>Patients and methods:</b> The study included 48 endoscopists who each performed at least 20 colonoscopies in the colonoscopy arm of a randomized controlled trial comparing fecal immunochemical test vs. colonoscopy in colorectal cancer screening. These endoscopists performed a total of 3838 procedures in the trial. The following were calculated for each endoscopist: adenoma detection rate (ADR), advanced ADR, proximal ADR, distal ADR, and adenoma per colonoscopy rate (APCR). The characteristics of endoscopists were assessed with regard to colonoscopy quality using multivariate regression analysis. Endoscopist characteristics included age, sex, exclusive endoscopy practice, years as a physician, years as a specialist, specialty, total (life-long) number of colonoscopies performed, annual colonoscopy volume, number of hours/week dedicated to endoscopy and number of educational activities in the previous year. <b>Results:</b> Factors associated with ADR were age of the endoscopist (odds ratio [OR] 1.11, 95 % confidence interval [CI] 1.01 – 1.21; <i>P</i> = 0.01) and life-long number of colonoscopies (OR 1.06, 95 %CI 1.01 – 1.11; <i>P</i> = 0.01). Only exclusive dedication to endoscopy practice was found to be independently related to proximal ADR (OR 1.71, 95 %CI 1.15 – 2.74; <i>P</i> = 0.001). Life-long number of colonoscopies was independently related to detection of distal adenomas (OR 1.07, 95 %CI 1.01 – 1.13; <i>P</i> = 0.01). None of the analyzed endoscopist characteristics was associated with advanced ADR or APCR. <b>Conclusions:</b> This study found that the experience of the endoscopist and exclusive dedication to endoscopy practice, but not annual colonoscopy volume, were associated with better colonoscopy quality.
Antibodies to the R component of Epstein-Barr Virus-Induced Early Antigens in Burkitt's Lymphoma Exceeding in Titer Antibodies to Epstein-Barr Viral Capsid Antigen2
Authors: Werner Henle, Gertrude Henle
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Antibodies to the R component of Epstein-Barr Virus-Induced Early Antigens in Burkitt's Lymphoma Exceeding in Titer Antibodies to Epstein-Barr Viral Capsid Antigen Get access Werner Henle, Werner Henle Search for other works by this author on: Oxford Academic PubMed Google Scholar Gertrude Henle Gertrude Henle Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 3, March 1977, Pages 785–786, https://doi.org/10.1093/jnci/58.3.785 Published: 01 March 1977 Article history Received: 09 June 1976 Accepted: 02 September 1976 Published: 01 March 1977
Development of a Robust and User-Friendly Method for Leukemia Classification Using Microarrays.
Authors: Wen Wei, Julie Tsai, Barbara Brady, Wei-min Liu, Xiaoying Chen, Rui Li, Sunhee Ro, James Sun, Alexander Kohlmann, Stuart Palmer, Raymond Wong, Khusbeer Malhotra, James Novotny, Mickey Williams
Journal: Blood (2006)
Total Nevi, Atypical Nevi, and Melanoma Thickness
Authors: Alan C. Geller, Jonathan E. Mayer, Arthur J. Sober, Donald R. Miller, Giuseppe Argenziano, Timothy M. Johnson, Susan M. Swetter
Journal: JAMA Dermatology (2016)

<h3>Importance</h3> Nevi are among the strongest risk factors for melanoma. However, little is known about the association of many total nevi (TN) or atypical nevi (AN) with tumor thickness. <h3>Objectives</h3> To examine the association between age and the number of TN and AN and to explore whether there was a relationship between TN or AN and tumor thickness, controlling for multiple variables. <h3>Design, Setting, and Participants</h3> Survey of patients with melanoma at 2 academic sites and an affiliated Veteran Affairs medical center. Participants included 566 patients surveyed within 3 months of diagnosis. Patients were surveyed in the melanoma clinics from May 17, 2006, through March 31, 2009, within 3 months of diagnostic biopsy. The dates of the analysis were April 1, 2015, to August 1, 2015. <h3>Main Outcomes and Measures</h3> Counts of TN and AN were performed at the first visit after diagnosis and were categorized as 0 to 20, 20 to 50, or more than 50 for TN and as 0, 1 to 5, or more than 5 for AN. Tumor thickness was categorized as 2.00 mm or less or as 2.01 mm or greater. All analyses were stratified by patient age (&lt;60 or ≥60 years). Logistic regression was used to test associations, controlling for age, sex, anatomic location of melanoma, institution, histologic subtype, marital status, performance of skin self-examination, number of health care visits in the past year, mode of melanoma discovery, and receipt of skin examination by a physician. <h3>Results</h3> The study population included 566 patients. Their mean (SD) age was 56.7 (15.9) years, and 39.0% (n = 221) were female. Of 566 patients, the number of TN was classified as 0 to 20 (66.4% [n = 376]), 20 to 50 (20.5% [n = 116]), or more than 50 (13.1% [n = 74]). Atypical nevus counts were 0 (73.3% [n = 415]), 1 to 5 (14.5% [n = 82]), or more than 5 (12.2% [n = 69]). For those younger than 60 years, the presence of more than 50 TN was associated with a sharply reduced risk of thick melanoma (odds ratio, 0.32; 95% CI, 0.12-0.81), and the presence of more than 5 AN compared with no AN was associated with thicker melanoma (odds ratio, 2.43; 95% CI, 1.02-5.75). <h3>Conclusions and Relevance</h3> Most patients with melanoma had few nevi and no AN. In younger patients (&lt;60 years), thick melanomas were commonly found in those with fewer TN but more AN, suggesting that physicians and patients should not rely on the total nevus count as a sole reason to perform skin examinations or to determine a patient's at-risk status. Younger patients should be educated on the increased risk of thicker melanomas that is associated with having more AN.
Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin
Authors: Navid M. Farsijani, Qingdu Liu, Hanako Kobayashi, Olena Davidoff, Feng Sha, Joachim Fandrey, T. Alp Ikizler, Paul M. O’Connor, Volker H. Haase
Journal: Journal of Clinical Investigation (2016)

The adult kidney plays a central role in erythropoiesis and is the main source of erythropoietin (EPO), an oxygen-sensitive glycoprotein that is essential for red blood cell production. Decreases of renal pO2 promote hypoxia-inducible factor 2-mediated (HIF-2-mediated) induction of EPO in peritubular interstitial fibroblast-like cells, which serve as the cellular site of EPO synthesis in the kidney. It is not clear whether HIF signaling in other renal cell types also contributes to the regulation of EPO production. Here, we used a genetic approach in mice to investigate the role of renal epithelial HIF in erythropoiesis. Specifically, we found that HIF activation in the proximal nephron via induced inactivation of the von Hippel-Lindau tumor suppressor, which targets the HIF-α subunit for proteasomal degradation, led to rapid development of hypoproliferative anemia that was associated with a reduction in the number of EPO-producing renal interstitial cells. Moreover, suppression of renal EPO production was associated with increased glucose uptake, enhanced glycolysis, reduced mitochondrial mass, diminished O2 consumption, and elevated renal tissue pO2. Our genetic analysis suggests that tubulointerstitial cellular crosstalk modulates renal EPO production under conditions of epithelial HIF activation in the kidney.
Effect of 5-Fluorouracil and Actinomycin D on Repair of DNA Single-Strand Breaks in Cervix Cancer Cells2
Authors: John E. Byfield, Young Chang Lee
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Effect of 5-Fluorouracil and Actinomycin D on Repair of DNA Single-Strand Breaks in Cervix Cancer Cells Get access John E. Byfield, John E. Byfield University of California, Laboratory of Nuclear Medicine, 900 Veteran Avenue, Los Angeles, California 90024 Search for other works by this author on: Oxford Academic PubMed Google Scholar Young Chang Lee Young Chang Lee University of California, Laboratory of Nuclear Medicine, 900 Veteran Avenue, Los Angeles, California 90024 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 2, February 1973, Pages 573–575, https://doi.org/10.1093/jnci/50.2.573 Published: 01 February 1973 Article history Received: 24 November 1972 Accepted: 08 December 1972 Published: 01 February 1973
Viruses and Renal Carcinoma of &lt;italic&gt;Rana pipiens&lt;/italic&gt;. XIII. Transmission of the Lucke Tumor by Herpesvirus-Containing Ascitic Fluid From a Tumor-Bearing Frog&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Robert F. Naegele, Allan Granoff
Journal: JNCI Journal of the National Cancer Institute (1972)

Transmission of the frog renal adenocarcinoma (Lucké tumor) was demonstrated with herpesvirus-containing ascitic fluid from a tumor-bearing frog. This finding may relate to the natural transmission of the Lucké tumor.
American Cancer Society Changes Breast Cancer Screening Guidelines To Reflect Analysis of Benefits and Harms
Authors: Marilyn Fenichel
Journal: JNCI Journal of the National Cancer Institute (2016)

NEWS | 5 of 8 in elderly patients who cannot tolerate induction chemotherapy, targets this gene."A next-generation hypomethylator, guadecitabine, or SGI-110, has a longer half-life and has shown activity in AML in a phase III study, and in phase I and II studies has shown activity that compares favorably to decitabine, based on historical controls," Issa said.An 800-patient phase III recently began in treatment-naïve patients who cannot induction chemotherapy, and earlierstage studies are ongoing.
Feline Malignant Mammary Tumors. I. Morphology and Biology: Some Comparisons With Human and Canine Mammary Carcinomas2
Authors: K. Weijer, K. W. Head, W. Misdorp, J. F. Hampe
Journal: JNCI Journal of the National Cancer Institute (1972)

Journal Article Feline Malignant Mammary Tumors. I. Morphology and Biology: Some Comparisons With Human and Canine Mammary Carcinomas Get access K. Weijer, K. Weijer Search for other works by this author on: Oxford Academic PubMed Google Scholar K. W. Head, K. W. Head Search for other works by this author on: Oxford Academic PubMed Google Scholar W. Misdorp, W. Misdorp Search for other works by this author on: Oxford Academic PubMed Google Scholar J. F. Hampe J. F. Hampe Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 49, Issue 6, December 1972, Pages 1697–1704, https://doi.org/10.1093/jnci/49.6.1697 Published: 01 December 1972 Article history Received: 26 June 1972 Accepted: 08 August 1972 Published: 01 December 1972